ArticleExperimental and therapeutic medicine2018
Decreased expression of microRNA-223 promotes cell proliferation in hepatocellular carcinoma cells via the insulin-like growth factor-1 signaling pathway.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- IGF-1R inhibitors in cancer: A review of available evidence and future outlook.Critical reviews in oncology/hematology · 2025Review
- Hsa_circ_0048674 facilitates hepatocellular carcinoma progression and natural killer cell exhaustion depending on the regulation of miR-223-3p/PDL1.Histology and histopathology · 2022Article
- Sustained Morphine Delivery Suppresses Bone Formation and Alters Metabolic and Circulating miRNA Profiles in Male C57BL/6J Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- HDAC10 Inhibits Cervical Cancer Progression through Downregulating the HDAC10-microRNA-223-EPB41L3 Axis.Journal of oncology · 2022Article
- Diagnostic and prognostic roles of circulating miRNA-223-3p in hepatitis B virus-related hepatocellular carcinoma.PloS one · 2020Article
- Genetic and Epigenetic Modifiers of Alcoholic Liver Disease.International journal of molecular sciences · 2018Review
- The Role of MicroRNAs in Hepatocellular Carcinoma.Journal of Cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most harmful types of cancer. Previous studies have demonstrated that microRNA (miR)-223 is downregulated in the serum and tumor tissue of patients with HCC. The present study aimed to investigate the regulatory role of miR-223 on insulin-like growth factor-1 receptor (IGF-1R) and downstream factors in HCC. The Hep3B cell line was transfected with miR-223 mimic and inhibitor. Following transfection, cell proliferation was analyzed using a cell counting kit 8 assay and cellular apoptosis was assessed using flow cytometry. The expression of key molecules in the IGF-1 signaling pathway, including IGF-1R, protein kinase B (Akt) and extracellular signal-regulated kinase (ERK) were determined using reverse transcription-quantitative polymerase chain reaction and western blot analysis. The results demonstrated that the mRNA and protein levels of IGF-1R were decreased in cells transfected with miR-223. Transfection with miR-223 also decreased cell proliferation and promoted cell apoptosis. Expression of total Akt and ERK, and their active forms phosphorylated Akt and ERK, were also downregulated following transfection with miR-223. By contrast, transfection with miR-223 inhibitor did not induce any effects on Hep3B cell proliferation and apoptosis, and did not affect the expression of key molecules in the IGF-1 pathway. Therefore, the results of the present study indicate that miR-223 decreases the proliferation and promotes the apoptosis of HCC cells. Its molecular mechanism of action may at least partially occur via the direct regulation of IGF-1R and indirect reduction of the downstream molecules Akt and ERK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.